INSTRUCTIONS New Drugs 2019, part 3
TEST INSTRUCTIONS
* Read the article. The test for this CE activity is to be taken online at http://www.nursingcenter.com/CE/nursing.
* You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you.
* There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost.
* For questions, contact Lippincott Professional Development: 1-800-787-8985.
* Registration deadline is June 4, 2021.
PROVIDER ACCREDITATION
Lippincott Professional Development will award 1.5 contact hours and 1.5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223.
Payment: The registration fee for this test is $17.95.
New Drugs 2019, part 3
GENERAL PURPOSE: To provide information about seven drugs recently approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe indications for seven newly approved drugs. 2. Identify nursing implications for these new drugs.
1. Baloxavir is indicated
a. to treat influenza within 3 days of symptom onset.
b. to treat acute uncomplicated influenza in patients age 12 and older.
c. for routine influenza prophylaxis.
2. The appropriate dose of baloxavir for a patient weighing 203 lb (92 kg) is
a. 40 mg.
b. 80 mg.
c. 120 mg.
3. The International Headache Society defines chronic migraine as
a. 15 or more MMD for more than 3 months.
b. 15 or more MMD for more than 6 months.
c. 4 to 14 MMD for more than 3 months.
4. Which statement about erenumab is correct?
a. It is indicated to prevent migraine in adults and children.
b. It is useful for patients with medication overuse headache.
c. It is a CGRP antagonist.
5. Erenumab is administered
a. orally.
b. I.V.
c. subcutaneously.
6. Before administering erenumab the nurse should
a. assess the patient for latex sensitivity.
b. warm the autoinjector by using a heat source such as hot water.
c. inform the patient that somnolence is a potential adverse reaction.
7. Which CGRP antagonist can be administered quarterly?
a. galcanezumab
b. erenumab
c. fremanezumab
8. The 675 mg dose of fremanezumab is administered as
a. a single injection.
b. three consecutive injections of 225 mg each.
c. three divided doses given a week apart.
9. Which statement about galcanezumab is correct?
a. It may be administered I.V.
b. Hypersensitivity reactions may occur days after administration.
c. Diarrhea is the most common adverse reaction.
10. The initial loading dose for galcanezumab is
a. 120 mg administered as one injection.
b. 160 mg administered as two consecutive injections of 80 mg each.
c. 240 mg administered as two consecutive injections of 120 mg each.
11. CBD is approved for treating seizures associated with Dravet syndrome or LGS in patients age
a. 2 months and older.
b. 2 years and older.
c. 12 years and older.
12. Which statement about CBD is accurate?
a. It does not cause euphoria or intoxication.
b. It is currently a Schedule I drug.
c. It is not extracted from the Cannabis sativa plant.
13. Possible adverse reactions to CBD include elevations in serum
a. troponins.
b. lymphocytes.
c. transaminases.
14. Teach patients taking CBD to
a. discard any solution remaining 2 weeks after the bottle is opened.
b. report any disturbing mood changes to the healthcare provider.
c. store the medication in the refrigerator.
15. Revefenacin is administered via oral inhalation using a(n)
a. MDI.
b. nebulizer.
c. dry powder inhaler.
16. Which statement about revefenacin is correct?
a. It is indicated to treat acute COPD symptoms.
b. It is not recommended for use in patients with hepatic impairment.
c. It is contraindicated in patients also using a short-acting beta2-adrenergic agonist.
17. Which statement about tafenoquine is correct?
a. It can help prevent relapses of malaria in certain patients.
b. It is given as a solo agent to treat acute malaria.
c. It must be taken for 14 days to be effective.
18. Before starting tafenoquine therapy, patients should be evaluated for
a. hypertension.
b. type 2 diabetes.
c. G6PD deficiency.